Polynovo Ltd
Company Profile
Business description
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
Contact
320 Lorimer Street
Unit 2
Port MelbourneVIC3207
AUST: +61 386814050
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
30 June 2025
Employees
8
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,633.10 | 66.10 | 0.77% |
CAC 40 | 7,223.92 | 10.60 | 0.15% |
DAX 40 | 19,226.24 | 80.07 | 0.42% |
Dow JONES (US) | 43,870.35 | 461.88 | 1.06% |
FTSE 100 | 8,226.16 | 76.89 | 0.94% |
HKSE | 19,229.97 | 371.14 | -1.89% |
NASDAQ | 18,972.42 | 6.28 | 0.03% |
Nikkei 225 | 38,283.85 | 257.68 | 0.68% |
NZX 50 Index | 13,041.90 | 276.66 | 2.17% |
S&P 500 | 5,948.71 | 31.60 | 0.53% |
S&P/ASX 200 | 8,393.80 | 70.80 | 0.85% |
SSE Composite Index | 3,267.19 | 103.21 | -3.06% |